Mannitol 15 % w/v Viaflo inf. opl. i.v. Belgia - nederlandsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo inf. opl. i.v.

baxter sa-nv - mannitol 15 g/100 ml - oplossing voor infusie - mannitol 150 mg/ml - mannitol

Mannitol 15 % w/v Viaflo sol. perf. i.v. Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mannitol 15 % w/v viaflo sol. perf. i.v.

baxter sa-nv - mannitol 15 g/100 ml - solution pour perfusion - mannitol 150 mg/ml - mannitol

MANNITOL injection, solution USA - engelsk - NLM (National Library of Medicine)

mannitol injection, solution

b. braun medical inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 20 g in 100 ml - mannitol injection is indicated for: - reduction of intracranial pressure and treatment of cerebral edema. - reduction of elevated intraocular pressure. mannitol injection is contraindicated in patients with: - hypersensitivity to mannitol [see warnings and precautions (5.1)] - anuria [see warnings and precautions (5.2)] - severe hypovolemia [see warnings and precautions (5.4)] - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] -   active intracranial bleeding except during craniotomy. the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.  mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) .  no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal

MANNITOL injection, solution USA - engelsk - NLM (National Library of Medicine)

mannitol injection, solution

hospira, inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 5 g in 100 ml - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] . - active intracranial bleeding except during craniotomy. risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) .no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in resp

MANNITOL injection, solution USA - engelsk - NLM (National Library of Medicine)

mannitol injection, solution

general injectables & vaccines, inc - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 250 mg in 1 ml - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)]. - active intracranial bleeding except during craniotomy. 8.1 pregnancy risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data).no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes i

MANNITOL/DEMO SOL.IV.INF 20% (W/V) Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

mannitol/demo sol.iv.inf 20% (w/v)

demo abee 21 ΧΛΜ. ΕΘΝ.ΟΔΟΥ ΑΘΗΝΩΝ-ΛΑΜΙΑΣ, 145 68 145 68, ΚΡΥΟΝΕΡΙ 8161802 - mannitol - sol.iv.inf (ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ) - 20% (w/v) - mannitol 200mg - mannitol

MANNITOL/DEMO 20% W/V SOLUTION FOR INTRAVENOUS INFUSION Kypros - gresk - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

mannitol/demo 20% w/v solution for intravenous infusion

the star medicines importers co. ltd (0000003109) 10 loukis akritas str, lemesos, 3030 - mannitol - solution for intravenous infusion - 20% w/v - mannitol (0000069658) 20g - mannitol

MANNITOL/FRESENIUS SOL.INF 20% Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

mannitol/fresenius sol.inf 20%

fresenius kabi hellas ae Λεωφ. Κηφισίας 64Α, 151 25 Μαρούσι Αττικής 6542909 - mannitol - sol.inf (ΔΙΑΛΥΜΑ ΓΙΑ ΕΓΧΥΣΗ) - 20% - mannitol 200g - mannitol

MANNITOL/ΒΙΟΣΕΡ INJ.SO.INF 20% Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

mannitol/βιοσερ inj.so.inf 20%

ΒΙΟΣΕΡ Α.Ε. ΒΙΟΜΗΧΑΝΙΑ ΠΑΡΕΝΤΕΡΙΚΩΝ ΔΙΑΛΥΜΑΤΩΝ Δ.Τ. ΒΙΟΣΕΡ Α.Ε. 9ο χλμ. Εθνικής Οδού Τρικάλων-Λάρισας, 421 00 Ταξιάρχες, Τρίκαλα 2431 083441-2 - mannitol - inj.so.inf (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ) - 20% - mannitol 200mg - mannitol

MANNITOL irrigant USA - engelsk - NLM (National Library of Medicine)

mannitol irrigant

b. braun medical inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 5 g in 100 ml - 5% mannitol is indicated for use as a urologic irrigation fluid for transurethral prostatic resection and other transurethral surgical procedures. 5% mannitol is not for injection. it is contraindicated in patients with anuria.